EVALUATION OF EMERGING IN-VITRO ASSAYS IN CERVICAL CANCER

EVALUATION OF EMERGING IN-VITRO ASSAYS IN CERVICAL CANCER
Author(s):
Geetanjali Tambe, H.J.Pagar, NehaTongire, Snehal Jogdand
Keywords:
Cervical cancer, human papillomavirus, prevention
Abstract
Cervical cancer is one of the most common types of gynaecological cancer in women. It's also one of the most frequent cancers in women, and it's one of the few that may be detected and treated entirely at the precancerous stage. Cervical cancer is caused mostly by sexually transmitted diseases (STDs), as well as the Human Papillomavirus (HPV), particularly HPV-16 and HPV-18. In India, it is still a big public health issue for women. Cervical cancer strikes women between the ages of 55 and 59, and a large percentage of those diagnosed are in advanced stages of the disease. Cervical cancer vaccinations include prophylactic vaccines against HPV-16 and 18 therapeutic v. Premature sexual activity, teen pregnancy, family history, and oral contraceptives are all epidermal risk factors. This page discusses the history of cervical cancer, histological types, risk factors, prevention, therapy, and drugs approved to prevent cervical cancer. Squamous cell carcinoma is the most frequent kind of cervical cancer. Only persons who have never been infected with HPV benefit from the vaccines.
Article Details
Unique Paper ID: 154657 Publication Volume & Issue: Volume 8, Issue 12 Page(s): 47 - 52
Article Preview & Download

Share This Article

NCSST-2021

AICTE Sponsored National Conference on Smart Systems and Technologies

Last Date: 25th November 2021

LATEST INNOVATION’S AND FUTURE TRENDS IN MANAGEMENT

Last Date: 7th November 2021